series-a
Stage
1
Investors
About
Stylus Medicine develops in vivo genetic medicines that use engineered recombinases to insert therapeutic payloads into a safe-harbor site in the human genome, delivered via cell-targeted lipid nanoparticles; its initial focus is on enabling in vivo CAR-T therapies.
Explore Stylus Medicine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.